The shit nobody talks about
A man qualifies when symptoms sit on top of two morning totals that are actually low. A checklist and a doorstep vial are a different product.
I am not a clinic, and I am not selling shots. If the last sections fit you — fertility, prostate, sleep apnoea, a number that was never repeated — start there instead of a cart.
The fight is simple. Guideline-defined testosterone deficiency, treated by a physician who repeats morning labs, looks for a cause, and monitors — versus online and men’s clinics selling cypionate, pellets or gels off a symptom quiz, a finger-prick, or a single afternoon draw.
Endocrine Society, Bhasin and colleagues, 2018, recommendation 1.1: diagnose hypogonadism only in men with symptoms and signs of testosterone deficiency and unequivocally and consistently low serum total T, and/or free T when indicated. Recommendation 1.2: against routine screening of men in the general population. Technical remarks in the opened PDF: measure fasting morning total T on two separate mornings. Testosterone is suppressed by food and glucose and varies day to day. About 30% of men with an initial T in the hypogonadal range have a normal T on repeat. Do not test during acute illness or short-term opioid use.
AUA, Evaluation and Management of Testosterone Deficiency, published 2018, reviewed and validity confirmed 2024. Statements 2–3: diagnosis of low T only after two total T measurements on separate occasions, both early morning; clinical diagnosis only when low totals are combined with symptoms and/or signs. Statement 5: validated questionnaires are not recommended to define who is a candidate for therapy or to monitor response. Purpose section: “Total testosterone <300 ng/dL alone does not define testosterone deficiency.” Symptoms are “very non-specific and can be manifestations of other conditions (e.g., chronic fatigue, chronic stress, a depressed state).”
The FDA-approved labels Kin opened say the same thing in capital letters. Testosterone cypionate (Alvogen; DailyMed, label revised July 2025, page updated 19 August 2026) and Vogelxo gel: “Prior to initiating [product], confirm the diagnosis of hypogonadism by ensuring that serum testosterone concentrations have been measured in the morning on at least two separate days and that these serum testosterone concentrations are below the normal range.”
That does not authorise diagnosis from a website checklist, a 15-minute intake, or one non-morning, non-fasting, finger-prick result. It does not say if you feel bad at 350 ng/dL you deserve shots. AUA and Endocrine Society both require low totals, or indicated free T, plus symptoms. Endocrine Society explicitly prefers not to label or treat men without unequivocally low T.
“Low” is not a vibe. Two cutoffs, both real, neither an optimisation target. AUA statement 1: clinicians should use total T below 300 ng/dL as a reasonable cutoff (Moderate, Grade B). Prefer the same lab and assay. Target on treatment: middle tertile; the panel defines success as 450–600 ng/dL with symptom and sign improvement. Endocrine Society Figure 1: the lower limit of the normal total testosterone harmonised to the CDC standard in healthy nonobese young men is 264 ng/dL (9.2 nmol/L), for CDC-certified assays. Harmonised range cited as 264–916 ng/dL (2.5th to 97.5th percentile). Those are not interchangeable “optimisation” targets of 600–800 ng/dL.
Measure free T when SHBG is altered, or when total T is near the limit. Endocrine Society Table 2 example of that borderline zone: 200–400 ng/dL. Method: equilibrium dialysis or a validated calculation. Analog “direct” free-T immunoassays are inaccurate; do not use them. Conditions that lower SHBG, so total T can look low while free T is normal: obesity, diabetes, glucocorticoids, hypothyroidism, nephrotic syndrome, acromegaly. Conditions that raise SHBG, so total T can look “normal” while free T is low: ageing, HIV, cirrhosis, hyperthyroidism, some anticonvulsants, oestrogens.
After biochemical confirmation, look for a cause. Endocrine Society recs 1.3–1.4: distinguish primary versus secondary with LH and FSH, then evaluate etiology. Functional and secondary causes in Table 1 include severe obesity, some sleep disorders, opioids, glucocorticoids, anabolic-androgen withdrawal, systemic illness. AUA statements 6–8: measure LH in men with low T; measure prolactin if LH is low or low-normal; evaluate persistently high prolactin. AUA statement 21: all men with testosterone deficiency should be counselled on lifestyle modifications as a treatment strategy. Low total T in an obese man is not automatically an indication for exogenous T. Obesity can lower SHBG and is a potentially reversible functional cause.
Lincoff, Bhasin, Flevaris and colleagues, New England Journal of Medicine 2023: in men who actually met a trial definition of hypogonadism — symptoms plus two fasting morning T below 300 ng/dL — and who had cardiovascular disease or high cardiovascular risk, transdermal 1.62% testosterone gel was noninferior to placebo for major adverse cardiac events. That is not a safety stamp for unsupervised shots, supra-physiologic “optimisation,” or men who were never properly diagnosed.
Design: multicentre, randomised, double-blind, placebo-controlled noninferiority trial. 5,246 men (Cleveland Clinic summary of randomised: 5,204), aged 45–80, preexisting or high risk of CVD, symptoms of hypogonadism, two fasting testosterone levels below 300 ng/dL. Daily transdermal 1.62% gel titrated to 350–750 ng/dL, haematocrit held at or below 54%, or placebo gel. Mean treatment 21.7 ± 14.1 months; mean follow-up 33.0 ± 12.1 months. Numbers here are from the opened structured abstract plus the investigator summary of the NEJM paper. Kin did not open the full NEJM PDF on this pass.
Primary MACE — cardiovascular death, nonfatal MI, or nonfatal stroke: 182 (7.0%) on testosterone versus 190 (7.3%) on placebo. Hazard ratio 0.96 (95% CI 0.78–1.17). P<0.001 for noninferiority, pre-specified upper CI bound below 1.5. Higher incidence on testosterone, from the Cleveland Clinic summary of the NEJM report: atrial fibrillation 3.5% versus 2.4%; acute kidney injury 2.3% versus 1.5%; pulmonary embolism 0.9% versus 0.5%. High discontinuation, about 61% in both arms, noted as a limitation. Protocol excluded congenital or severe hypogonadism (T below 100 ng/dL).
Lincoff, Cleveland Clinic: findings apply to middle-aged and older men with confirmed hypogonadism — symptoms plus at least two properly measured morning T below 300. Nissen: “This study should not be used as a justification for the widespread prescription of testosterone to aging men.” It does not show cardiovascular safety for injectable cypionate, pellets, compounded cream, or oral T. The product studied was 1.62% gel under protocol titration. It does not show safety in men who fail two-morning diagnosis, who are treated to 600–800 and above as “optimal,” or who are not haematocrit-monitored. Noninferiority on MACE is not “no harm.” Pulmonary embolism, atrial fibrillation and acute kidney injury signals remain. Symptom benefit was not the primary endpoint of this safety trial.
FDA, 28 February 2025, after reviewing TRAVERSE: adding TRAVERSE results to all testosterone product labels; removing language from the Boxed Warning related to an increased risk of adverse cardiovascular outcomes; retaining “Limitation of Use” language for age-related hypogonadism; and, from required ambulatory blood-pressure studies, adding a warning that testosterone products increase blood pressure, class-wide. AUA statement 20, 2018 text still on the 2024-confirmed page, still reads that cardiovascular risk cannot be stated definitively. That sentence is pre-TRAVERSE. It should not be presented as the last word, and it should not be silently deleted.
On the U.S. labels Kin opened, testosterone is indicated for primary hypogonadism or hypogonadotropic hypogonadism due to testicular, pituitary or hypothalamic disease. Not “feel younger.” Primary: testicular failure — cryptorchidism, torsion, orchitis, orchiectomy, Klinefelter, and the rest. Hypogonadotropic: GnRH or gonadotropin deficiency, or pituitary-hypothalamic injury from tumours, trauma, radiation.
Limitation of Use, still on the July 2025 cypionate label opened in September 2026: “Safety and efficacy of testosterone cypionate injection in men with ‘age-related hypogonadism’ (also referred to as ‘late-onset hypogonadism’) have not been established.” Same limitation on the 2019 Vogelxo label. The 2015 FDA Drug Safety Communication: testosterone is approved only for men with low T caused by certain medical conditions; “The benefit and safety of these medications have not been established for the treatment of low testosterone levels due to aging, even if a man’s symptoms seem related to low testosterone.”
Boxed warning mismatch is a reporter trap. I am going to be tedious about it. Vogelxo gel boxed warning, opened PDF: WARNING: SECONDARY EXPOSURE TO TESTOSTERONE — virilisation in children who contact unwashed or unclothed application sites. Not a cardiovascular boxed warning on this gel label. Cypionate DailyMed, opened: no boxed warning. The 2025 FDA action is take cardiovascular language out of the box where it existed. Blood pressure is a new warning, not shown as a new box on the cypionate label opened. Polycythaemia is haematocrit monitoring in Warnings, not boxed. Do not write that the boxed warning is blood pressure, cardiovascular disease, and polycythaemia. It is not.
Cypionate warnings include venous thromboembolism (DVT/PE); a remaining paragraph that cardiovascular studies have been “inconclusive” and some studies reported increased MACE; “Testosterone can increase blood pressure which can increase cardiovascular (CV) risk over time. Monitor blood pressure periodically… not recommended for use in patients with uncontrolled hypertension.” Haematocrit and haemoglobin periodically, to detect polycythaemia; oligospermia after prolonged or high-dose use; contraindicated in known or suspected prostate or breast cancer. Cypionate “has not been shown to be safe and effective for the enhancement of athletic performance.”
Vogelxo 5.3, polycythaemia: check haematocrit before treatment, at 3–6 months, then annually; if elevated, stop until acceptable; increased red-cell mass may increase thromboembolic risk. 5.8, spermatogenesis: exogenous androgens may suppress FSH and sperm count. 5.12, sleep apnoea: testosterone may potentiate OSA, especially with obesity or chronic lung disease. Monitor PSA, haematocrit, lipids.
HHS, 18 June 2026: FDA is requesting further label updates — remove the age-related and idiopathic hypogonadism limitation of use; contraindicate testosterone only in metastatic prostate cancer; revise BPH language. HHS cites TRAVERSE (“more than 5,200 men”) as finding “no meaningful increase” in MACE. Prostate: “important uncertainties remain because prostate cancer can take years to develop.” That note is a request. The cypionate label opened after that date still carried the age-related limitation. I am not going to treat the request as already-on-the-bottle law.
Exogenous testosterone is contraception-adjacent. It is not a rare asterisk. Endocrine Society rec 2.2: recommend against testosterone therapy in men planning fertility in the near term. Also against it in breast or prostate cancer, an unevaluated prostate nodule, PSA above 4 or above 3 in high-risk men without urology, elevated haematocrit, untreated severe obstructive sleep apnoea, severe lower urinary tract symptoms, uncontrolled heart failure, MI or stroke within 6 months, thrombophilia. Fertility paragraph in the opened PDF: “T therapy suppresses spermatogenesis and is not appropriate in men with hypogonadotropic hypogonadism who desire fertility in the next 6 to 12 months.”
AUA 23 (Strong, Grade A): exogenous T should not be prescribed to men currently trying to conceive. AUA 16: discuss the long-term impact of exogenous T on spermatogenesis with men interested in future fertility (Strong, Grade A). AUA 10: reproductive-health evaluation before treatment if fertility matters. AUA cites contraceptive-trial recovery data in healthy eugonadal men (Liu and colleagues): probability of sperm concentration above 20 million/mL 67% by 6 months, 90% by 12, 96% by 16, 100% by 24 — and immediately warns this may not generalise to testosterone-deficient or infertile men. Some infertile men never recover (Wenker and colleagues, as cited by AUA). “Temporary and always reversible in 6–12 months” is not what AUA or Endocrine Society say for the clinic population. Recovery data AUA quotes are from contraceptive studies in healthy men with normal baseline T and sperm.
Clomiphene, hCG and aromatase inhibitors are not FDA-approved testosterone replacement for this indication (AUA Table 6 footnotes; Endocrine Society: clomiphene used empirically, efficacy and safety not shown in RCTs). Marketing them as “TRT that preserves fertility” is off-label.
Prostate first, because both slogans are wrong. Testosterone is contraindicated in known or suspected prostate cancer on the current opened labels. HHS June 2026 requests narrowing that to metastatic prostate cancer; that change was not on the cypionate label opened here. Endocrine Society: against T if prostate cancer, a palpable nodule or induration, PSA above 4 ng/mL, or PSA above 3 ng/mL in high-risk men (African American, first-degree relative) without further urology. Rec 2.3: in hypogonadal men 55–69 with life expectancy over 10 years, discuss prostate-cancer risk and monitoring (shared decision); if monitoring, assess risk before T and 3–12 months after start. Rec 3.2: urology if confirmed PSA rise more than 1.4 ng/mL above baseline, confirmed PSA above 4.0, or DRE abnormality in year 1. AUA 12 (Clinical Principle): measure PSA in men over 40 before starting T to exclude prostate cancer. AUA 17: inform patients of the absence of evidence linking T therapy to development of prostate cancer (Strong, Grade B). AUA 18: history of prostate cancer — inadequate evidence to quantify risk-benefit (Expert Opinion). Table 7: haematocrit keep below 54%; PSA per AUA early-detection guideline after shared decision. Absence of a proven causal link to de novo prostate cancer is not permission to skip monitoring. TRAVERSE was not a prostate-cancer outcome trial. HHS still flags follow-up too short for long-latency cancer. AUA’s “no evidence T causes prostate cancer” is not “PSA is optional in a telehealth funnel.”
Obesity, untreated severe obstructive sleep apnoea, and opioids are reasons to investigate, pause, or not start T — not background noise while the syringe ships. Endocrine Society Table 1, functional secondary causes: opioids, glucocorticoids, anabolic steroids, severe obesity, some sleep disorders, organ failure, systemic illness — “potentially reversible with treatment of the underlying etiology.” Educating patients that obesity or opioids may be contributing “could motivate them to lose weight or discontinue narcotic pain medications.” Rec 2.2: against starting T in untreated severe OSA and in elevated haematocrit. Do not test men recovering from acute illness or on short-term opioids that suppress T. Rec 2.6: against T as a means of improving glycaemic control in type 2 diabetes. AUA 4: consider measuring T in chronic narcotic use. AUA 11: measure haemoglobin/haematocrit before T and inform patients of increased polycythaemia risk (Strong, Grade A). AUA 24: do not commence T for 3–6 months after a cardiovascular event (Expert Opinion). Vogelxo 5.12: T may potentiate sleep apnoea. “Poor sleep” on a clinic quiz is not a substitute for diagnosing OSA before T, which can worsen OSA.
Prevalence sleight of hand, because you will see 40%. AUA Table 3: HIM study, Mulligan 2006, 38.7% on a single pre-noon total T below 300 or already on T. EMAS, Wu 2010: 2.1% when low T is combined with three sexual symptoms. Ads using “40% of men over 45” are quoting a screening lab rate, not Endocrine Society or AUA cases. AUA purpose section, citing Baillargeon and Malik: testing and prescriptions nearly tripled; estimates that up to 25% of men who receive T were not tested before initiation; nearly half not retested after; up to a third on T do not meet diagnostic criteria — while some who need T never get it. That is observational, not a new RCT. It is the funnel.
These URLs were opened as advertising. They are not evidence of who qualifies or of safety.
Arsenal Men’s Health, Utah telehealth, opened page: a symptom checklist (“this quick assessment helps determine if TRT may benefit you”). “Many doctors only treat when levels fall below 300 ng/dL… At Arsenal, we focus on how you feel, not just your lab numbers.” “If you’re experiencing symptoms at 350 ng/dL, you deserve treatment, even if that’s technically ‘normal.’” “We optimize for your optimal level (typically 600–800 ng/dL).” “Low testosterone (hypogonadism) affects nearly 40% of men over 45.” Funnel: free consult, Quest or LabCorp or at-home kit, meds to the door; weekly subcutaneous cypionate; also compounded cream “20x more powerful than commercial gels.” FAQ says they “recommend two morning testosterone measurements” then immediately undercuts the cutoff. TRAVERSE is cited as “Cardiovascular Safety Confirmed” and “The FDA subsequently removed cardiovascular warnings from testosterone labels. TRT is safe when properly monitored.”
Versus the documents: AUA cutoff is below 300 on two morning totals plus symptoms; AUA rejects questionnaires as diagnostic. Endocrine Society 264 on CDC assays; against treating without unequivocally low T. FDA label: two morning values below the normal range before initiating. AUA statement 28 prefers commercial over compounded T when possible. The 40% tracks HIM’s single-draw statistic, not guideline-defined deficiency. TRAVERSE was gel, two fasting morning T below 300, haematocrit cap. FDA removed cardiovascular boxed-warning language, added a blood-pressure warning, and kept the age-related limitation as of the 2025 FDA notice.
Shift, national telehealth: “Feel like yourself again.” “40% / Men over 45 have clinically low T.” Funnel: 15-minute online questionnaire, “Finger-prick lab kit… Takes 2 minutes at home,” 15-minute video consult, medication overnight. “Most TRT patients report noticeable energy, mood, and libido improvements in 3–6 weeks.” Combines TRT with ED drugs, GLP-1s, and peptides (BPC-157, CJC-1295). States meds are “FDA-approved products or compounded by licensed 503A/503B pharmacies.” Finger-prick and 2-minute at-home kits are not the Endocrine Society fasting morning venous total T on a CDC-certified assay, twice. A 15-minute questionnaire is exactly the case-finding instrument AUA statement 5 says not to use. Peptides named on the page are not testosterone-deficiency guideline therapy.
Enforcement, because I would rather you had the letters that exist than ones I invented. New York Attorney General Health Care Bureau Annual Report 2018: Ageless Men’s Health, P.C., 36 U.S. clinics, 3 in New York City. Investigation found a misleading “Low T Quiz”; failure to follow guidelines on time of day and number of tests; offering T to men above guideline thresholds without disclosing that; failure to inform patients that decreased fertility is a scientifically established side effect. Settlement: remove the quiz; tell patients guidelines call for two morning tests before TRT; disclose guideline thresholds; written fertility warning. FDA warning letter, Empower Clinic Services, LLC doing business as Empower Pharmacy, 25 May 2017: compounding without valid prescriptions for individually identified patients (failed 503A conditions); insanitary sterile practices; adulterated, misbranded, unapproved new drugs. That is manufacturing and compounding compliance, not an advertising letter about “low T” claims, and not proof every men’s-clinic vial is unsafe. A search of FTC.gov warning letters targeting TRT-clinic consumer ads did not yield a clinic “low T quiz” letter. I am not inventing one. FTC AndroGel litigation against AbbVie is patent and pay-for-delay, not clinic diagnosis.
If a man 45–65 has specific symptoms — especially reduced libido, reduced spontaneous erections, infertility, very small testes, unevaluated anaemia, low-trauma fracture — he should see endocrinology or urology, not a cart. Workup that matches the opened guidelines: two fasting morning venous total T, CDC-certified assay if possible; free T by equilibrium dialysis or a validated calculation if obese, diabetic, or total T around 200–400; LH and FSH, and prolactin if the pattern is secondary; screen for obesity, OSA, opioids, glucocorticoids, pituitary disease. Treat reversible causes first. Exogenous T only if he meets biochemical plus clinical criteria, is not trying to conceive, has haematocrit, PSA and blood pressure checked, and understands pulmonary embolism, atrial fibrillation, polycythaemia and sperm suppression. That is who actually qualifies.
What I will not dress up. A 15-minute telehealth, a finger-prick, and doorstep cypionate, pellets or compounded cream is not “doctor-guided TRT” equivalent to Endocrine Society and AUA care. TRAVERSE is not a billboard that TRT is heart-safe for men who never had two morning totals below 300. “40% of men over 45 have clinically low T” is a screening lab rate. 350 ng/dL plus fatigue is not a prescription. Fertility, haematocrit, blood pressure and OSA are not fine print you hide under a quiz.
No. Not from me, and not from a cart that starts with a quiz. If you meet the diagnosis, the prescription is a physician’s job, on a labelled product, with monitoring. AUA prefers FDA-approved commercial products over compounded T when possible. I am not ranking clinics and I am not linking a vial.
This piece is about who the opened guidelines say qualifies, and what the funnel skips. It is not a prescription, and I am not in a position to diagnose you. Go to endocrinology or urology, not a comment section, if any of this fits: the specific symptoms above; a lump, a rising PSA, or known prostate disease; you are trying to conceive or might want to; untreated sleep apnoea; opioids; a haematocrit that is already high; recent heart attack or stroke; uncontrolled blood pressure; or a number from a single afternoon draw that someone has already offered to treat.
That list is not me diagnosing anything. A physician who will repeat a morning venous total, look for a cause, and monitor haematocrit, PSA and blood pressure will get further in one visit than a quiz will.
The claims in this piece were reviewed by Kin on 2 September 2026, against the primary records rather than summaries of them. Nothing here about the body was written before that review, and where Kin's ruling and a seller's claim disagree, Kin wins.
What I don't know: whether a particular man reading this is hypogonadal. Two morning venous totals plus a workup would tell him; a quiz will not. TRAVERSE does not settle injectable cypionate, pellets, compounded cream, or unsupervised “optimisation.” The June 2026 HHS note is a request, not the label Kin opened. No FTC clinic-ad warning letter was found, and I am not padding the gap with Reddit.